Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
Oramed Pharmaceuticals (ORMP): Key Trial Data and Portfolio Strategy in Focus

Oramed Pharmaceuticals (ORMP): Key Trial Data and Portfolio Strategy in Focus

Key Takeaways

  • Clinical inflection point: A focused 60-patient U.S. trial for the lead oral insulin candidate, ORMD-0801, is the central near-term data readout that could validate the company's refined, high-responder patient-subgroup strategy.
  • Strategic repositioning: Oramed's transfer of its Protein Oral Delivery (POD™) technology and its 49.99% stake in Lifeward signal an evolution from a pure clinical-stage biotech toward a diversified, capital-allocating platform.
  • Portfolio monetization: Returns from investments such as Scilex (including royalty streams) and Alpha Tau Medical are becoming a meaningful, non-dilutive source of value that could fund operations.
  • Analyst sentiment firming: Aggregate one-year price targets compiled by Fintel were revised upward to $7.14, and at least one ratings provider upgraded ORMP to a "Buy" rating in October 2026, though sell-side coverage remains thin.
  • Macro sensitivity: Small-cap biotech funding conditions, interest rates, and U.S. Food and Drug Administration (FDA) regulatory posture will heavily influence both financing flexibility and valuation.
  • Key risks: Clinical and regulatory attrition, limited analyst coverage, and execution risk tied to the Lifeward integration could alter the outlook.

Strategic Positioning and Competitive Outlook

Oramed Pharmaceuticals Inc. has historically built its identity around a platform for orally delivering injectable biologics, most notably oral insulin. Its Protein Oral Delivery (POD™) technology is designed to protect drug molecules and improve absorption through the gastrointestinal tract, potentially replacing injections for large chronic-disease markets. The lead candidate, ORMD-0801, targets type 2 diabetes, while an oral glucagon-like peptide-1 (GLP-1) receptor agonist candidate addresses a fast-growing metabolic-disease segment.

However, after a prior Phase 3 trial missed its primary endpoint, management pivoted toward a subgroup-driven strategy, identifying patient populations—such as those with lower body mass index (BMI) and older demographics—that showed clinically meaningful reductions in HbA1c (a measure of average blood sugar). This reframing, alongside the January 2026 agreement to transfer the POD™ technology to Lifeward while acquiring a 49.99% equity interest, positions Oramed less as a single-asset biotech and more as a strategic investor and platform operator. The medium-term competitive question is whether this diversified model can sustain value creation while the refined oral insulin program pursues validation independently. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Major Catalysts Ahead

Several forward-looking developments could shape investor sentiment. The most important is the data readout from the planned 60-patient U.S. clinical trial for ORMD-0801, which management designed to be cost-efficient and statistically focused on previously identified high-responder subgroups. Positive, reproducible results would materially de-risk the program and support further regulatory dialogue.

Earnings disclosures also matter: ORMP's third-quarter 2026 results are scheduled for November 16, 2026, with full-year fiscal 2026 results expected around March 3, 2027. Beyond financials, investors will watch commentary on portfolio monetization, including anticipated returns from the Scilex investment and associated royalties, as well as any progress integrating the Lifeward position.

On analyst ratings and price targets, the consensus profile has firmed modestly. Aggregate one-year price targets compiled by Fintel rose to $7.14 per share in September 2026, up roughly 12% from the prior $6.38 estimate, within a narrow range of $7.07 to $7.35. In October 2026, Weiss Ratings upgraded ORMP to a "Buy" rating. Coverage remains limited, so individual target revisions can carry outsized weight for a stock of this size.

Industry and Macroeconomic Forces

Oramed operates at the intersection of oral-biologics innovation and the metabolic-disease market, where demand for convenient, non-injectable therapies for diabetes and obesity remains structurally strong. The global injectable drug-delivery market is large, and oral alternatives could capture share if clinical and regulatory hurdles are cleared. Yet this is a capital-intensive, high-attrition arena, and the broader interest-rate environment directly affects both the discounting of future cash flows and the availability of growth capital for small-cap developers.

Regulatory climate is another pivotal force. FDA feedback on the refined trial design and any future pathway toward a Biological License Application (BLA)—the submission required to seek marketing approval for a biologic product—will shape timelines. Geopolitical and funding conditions also matter, given Oramed's earlier partnership efforts in China and its reliance on a diversified investment portfolio whose mark-to-market value can swing with biotech sector sentiment.

2026 Outlook and Long-Term Themes to Watch

Looking toward 2026 and beyond, Oramed's trajectory hinges on two parallel engines. First, the oral insulin program must demonstrate that a refined, subgroup-targeted approach can convert earlier signals into regulatory-grade evidence. Second, the investment portfolio and the Lifeward stake must continue generating returns that fund research and development (R&D) without excessive shareholder dilution.

Long-term themes include the durability of margins and cost structure as the company balances clinical spending against portfolio income, the pace of technology transition from injection-based to oral delivery, and competitive threats from larger players advancing oral GLP-1 and oral insulin programs. Capital-allocation priorities—buybacks, a contemplated one-time dividend, and selective investments—will increasingly define how the market values the company. Thin analyst coverage means consensus expectations can shift quickly, and externally published price targets should be read as analyst views rather than forecasts from this article. From what I see, I'm watching this closely for signs of execution on the new strategy.

Exploring AI-Driven Insights on ORMP

In my view, Tickeron's AI Trend Prediction Engine has been a useful addition to my routine when assessing stocks like this one. It provides data-driven forecasts on potential trends over the coming weeks or months, helping me cross-check fundamental views with quantitative signals without replacing core analysis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ORMP

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


ORMP's Indicator enters downward trend

The Aroon Indicator for ORMP entered a downward trend on November 16, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 184 similar instances where the Aroon Indicator formed such a pattern. In 153 of the 184 cases the stock moved lower. This puts the odds of a downward move at 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ORMP as a result. In 66 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.

The Moving Average Convergence Divergence Histogram (MACD) for ORMP turned negative on November 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 39 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORMP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ORMP's RSI Indicator exited the oversold zone, 25 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

ORMP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. ORMP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.506) is normal, around the industry mean (3.596). P/E Ratio (0.910) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.259) settles around the average of (131.631) among similar stocks. P/S Ratio (90.909) is also within normal values, averaging (443.347).

The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -4%. For the same Industry, the average monthly price growth was -12%, and the average quarterly price growth was -25%. VIVS experienced the highest price growth at 111%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 84%. For the same stocks of the Industry, the average monthly volume growth was 101% and the average quarterly volume growth was 38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 68
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company which engages in pharmaceutical preparations

Industry Biotechnology

Industry
Pharmaceuticals Other
Address
1185 Avenue of the Americas
Phone
+1 844 967-2633
Employees
13
Web
https://www.oramed.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
KLAR dropped -4.84% to $13.75 from Wednesday's close of $14.45, with the decline occurring during Thursday's regular session. JPMorgan downgraded the shares to Hold from Overweight and cut its price target to $17 from $20 in a note published before the open, extending a run of post-earnings target reductions.